Knight Therapeutics Inc. has shown a mixed performance this week, with a slight increase despite recent news.
This week, Knight Therapeutics Inc. (GUD.TO) experienced a modest gain of 0.83%, closing at C$9.77, while the stock faced a slight decline of 1.01% on Friday. With a year-to-date increase of 65.31%, investors are keenly observing the company's upcoming events and financial performance.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$969.03M
P/E
164.5x
52W high
$10.17
52W low
$5.66
1W change
+0.83%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 0.6% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$9.83
+0.6% Upside
Current Price
C$9.77
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
17.8%
Annualized
90-Day Vol
29.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.37 | C$9.75 – C$11.03 |
| 60 trading days | C$11.01 | C$10.09 – C$12.01 |
| 90 trading days | C$11.68 | C$10.50 – C$12.99 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Knight Therapeutics continues to demonstrate resilience with strong year-to-date performance, but the current technical indicators suggest a cautious approach as the company prepares to release its second-quarter results.
Knight Therapeutics Inc. Shows 65.31% Year-to-Date Gain
Despite recent fluctuations, the stock remains within 91% of its 52-week range, indicating a potential for continued growth or volatility.
Bull case
The company’s solid year-to-date performance reflects strong investor confidence and suggests potential for future growth, especially with the anticipated earnings releases.
Bear case
Even with positive year-to-date results, the high P/E ratio and low profit margins may raise concerns about sustainability and profitability for investors.
Recent Price Action
Advertisement
Knight Therapeutics Inc. saw a closing price of C$9.77 on Friday, marking a 1.01% decline for the day. However, the stock had a positive week overall, gaining 0.83%. Year-to-date, Knight Therapeutics has performed remarkably well, up 65.31%, which reflects strong investor interest and confidence in the company.
Company News
This week, Knight Therapeutics announced a conference call scheduled for July 30, 2026, to discuss its second-quarter results. This announcement could be a catalyst for future price movements as investors await insights into the company's performance and strategies.
Technical Picture
Analyzing the technical indicators, Knight Therapeutics is currently trading above its 50-day moving average of C$9.27, which is up 5.4% from the last close. The stock is also significantly above its 200-day moving average of C$7.17, indicating a strong upward trend over a longer period. The 52-week trading range is C$5.66 to C$10.17, positioning the stock at 91% of its range. With a beta of 0.05, the stock is considered to be less volatile compared to the broader market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
